Drug Controller General of India (DCGI) has given nod to Biocon and its partner Quark Pharmaceuticals to proceed with clinical trials on human subjects for a new drug candidate, 'QPI-1007' aimed for ocular neuroprotection. The company and Quark Pharmaceuticals have also randomized the first patient in India in the global Phase II/III study of the new drug candidate. Randomisation is the allocation of subjects to treatment groups to prevent selection and accidental bias.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
